Navigation Links
Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives
Date:5/28/2008

on-small cell lung cancer

in 2009.

New Targets Initiative to Feed Early-Stage Pipeline

HGS has a rich heritage of scientific discovery that has produced a vast intellectual property estate and a library of thousands of therapeutic and diagnostic targets. Over the past couple of years, HGS has conducted a careful review and selected approximately 50 targets for further research and potential development, with the goal of filing new IND's in 2010-2011.

HGS plans to develop the selected targets through co-development or research collaborations, as well as through its own internal research, including the application of antibody development technology from collaborators such as Cambridge Antibody Technologies and Xencor.

DARAPLADIB ADVANCING TO PHASE 3 TRIALS FOR THE TREATMENT OF ATHEROSCLEROSIS

Darapladib, a small-molecule inhibitor of Lp-PLA2, was discovered by GSK based on HGS technology. HGS will receive a 10% royalty on worldwide sales of darapladib if it is commercialized, and also has a 20% co-promotion option in North America and Europe.

In April 2008, GSK announced that it intends to advance darapladib to Phase 3 clinical trials as a potential treatment for atherosclerosis and will shortly start discussions with regulators regarding the structure of the darapladib Phase 3 program. Darapladib has the potential to be an important treatment for atherosclerosis.

At the American College of Cardiology's 57th Annual Scientific Session in March, GSK presented data from a randomized Phase 2 dose-ranging trial of darapladib in patients with coronary heart disease (CHD). The study showed that darapladib produced sustained, dose-dependent inhibition of plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) activity in patients receiving intensive atorvastatin (cholesterol-lowering) therapy. Lp-PLA2 is an enzyme associated with the formation of atherosclerotic plaques and identified in clinical trials as an independ
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
2. St. Jude Finds Dancing Hair Cells Are Key to Humans Acute Hearing
3. Increases in West Nile Virus Replikin Concentrations Precede Increases in the Number of Human Cases
4. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
5. Quantum Immunologics, Inc. and the South Alabama Medical Science Foundation Announce an Early Clinical Evaluation of a Novel Immuno-therapeutic Vaccine for Treating Advanced Human Breast Carcinomas
6. First Human Implant of New Archus Orthopedics Facet Replacement System
7. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
8. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
9. Data Show SuperGens MP-470 is Safe in Humans
10. Longevinex(R) Found to be Superior to Green Tea Molecule in Independent Human Study
11. CardioMind Launches First-in-Human Trial of Small Vessel, Drug-Eluting Stent

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... , BIRMINGHAM, Ala., Nov. 19 /PRNewswire-Firs... BCRX ) today announced the pricing of a public of...$9.75 per share, resulting in gross proceeds of $4... by BioCryst pursuant to an effective shelf regist...ies and Exchange Commission. BioCryst has also gr...
(Date:11/19/2009)... , LOVELAND, Colo., Nov. 19 /PRNewswire-First... its customers, experience, Heska Corporation (Nas...today the launch of its new and improved website. ... of analysis, design and programming to align the ...gic objectives. ,, (Logo: http://www.newscom...
(Date:11/19/2009)... , MOUNTAIN VIEW, Calif., Nov. 19 /PRNewswire-F... ALXA ) announced today that its corporate presen... Piper Jaffray Health Care Conference on Wednesday... presentation will be webcast from The New York Pa...omas B. King, Alexza President and CEO. ,, To...
Breaking Medicine Technology:BioCryst Announces Pricing of Public Offering of Common Stock 2BioCryst Announces Pricing of Public Offering of Common Stock 3Heska Announces Launch of New Website 2Heska Announces Launch of New Website 3Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Designer molecules being developed to fight disease 12603 1Designer molecules being developed to fight disease 12603 2Protest 3A AHF to Renew Call for California Condoms in Porn Law at Larry Flynts Hustler Hollywood Store 48810 1Protest 3A AHF to Renew Call for California Condoms in Porn Law at Larry Flynts Hustler Hollywood Store 48810 2Endologix Receives Nasdaq Letter on Director Independence 48808 1Endologix Receives Nasdaq Letter on Director Independence 48808 2
...nts, Wake After Sleep Onset and Total,Sleep Time, ...Persistent Sleep, were met at both doses - Evotec ... 10am EST) today , HAMBURG, Germany | OXFORD, Engl...hange: EVT) announced today positive top-line,resu...201 in,patients with chronic primary insomnia. EVT...
...ted at ASCO with cediranib - a selective,VEGF sign... alive,and progression- free at six months(1), CHI...nvestigational agent cediranib (AZD2171) were pres...Society of Clinical Oncology,(ASCO) from a study i...nvasive form of brain tumor with a high unmet medi...
Other Medicine Technology:Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 2Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 3Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line,Results with ... 4Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 2Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 3Investigational Drug Cediranib (AZD2171) Shows Promise in Patients,With Recurrent Glioblastoma (GBM) 4
(Date:11/21/2009)...PYneuron,s most popular and addictive game, SplitW...h. , Mountain View, CA (P...lar and addictive game, SplitWords, is now availab...signed to help banish that ,tip of the tongue, syn...ame challenges the brain by encouraging users to ...
(Date:11/20/2009)...v. 20 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuti...of Shareholders will be held on Monday, December 2... approval of two special resolutions. The first sp...ale of all or substantially all of the assets of N... the asset purchase agreement dated November 10, 2...
(Date:11/20/2009)...Nov. 20 Rates of infecti...d in late October, but the pandemic flu virus cont...ge groups, including the elderly, according to a n... DGX ), the world,s leading provider of diagnost...s most recent Quest Diagnostics Health Trends(TM) ...
(Date:11/20/2009)... The following is a stat...Nevada Health Care Association: ,, "The Nevada ... Senate Majority Leader Harry Reid for his leaders...goal of protecting every Nevada seniors, ongoing a... the strength and viability of our state,s vital f...
(Date:11/20/2009)...ber 20, 2009Emergency medical service (EMS) provid...00 cardiac arrests each year. Only 5 to 10 percen.... Better quality cardiopulmonary resuscitation (C...ssociated with better patient outcome. The Resusc...linical research network to study prehospital trea...
Breaking Medicine News(10 mins):Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
... Achilles, heel, report suggests , , THURS...Gleevec has forced metastatic melanoma into remiss...Dana-Farber Cancer Institute in Boston. , The case...e patient was enrolled in a clinical trail of the ...
... Sustainable Model for ...ngs, Inc.,(NYSE: ZMH ; SWX: ZMH) today announced ...model aimed at establishing an enhanced standard f...rve,the healthcare markets of the future., The re...
...earch, advocacy and ...hilia Foundation,(NHF) today announced its first-e... the Hemophilia Walk, presented nationally by Baxt...nding to,help find better treatments and cures for...
...ations, Inc. (Amex: IMA ), a global leader in rap...ced that it will release its first quarter,2008 ea...ll also host a,conference call beginning at 10:00 ...uestions concerning business and,financial develop...
...(Nasdaq: YDNT ) today announced that it will broa...ve and on-demand web cast conference call,on Thurs...live audio,broadcast of the call will be available... http://www.ydnt.com ., For those unable to liste...
...es in thinking skills, study finds , , THU...ions known as anticholinergic drugs -- used to tre...son,s disease and urinary incontinence -- may caus...on these drugs does worsen your cognitive performa...
Other Medicine News:Health News:Gleevec Pushes Advanced Melanoma Into Remission 2Health News:Zimmer Announces New Compliance Model 2Health News:Zimmer Announces New Compliance Model 3Health News:Zimmer Announces New Compliance Model 4Health News:Zimmer Announces New Compliance Model 5Health News:Zimmer Announces New Compliance Model 6Health News:Zimmer Announces New Compliance Model 7Health News:National Hemophilia Foundation Asks America to Make a Difference With National Fundraising Initiative 2Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results 2Health News:Young Innovations, Inc. Provides First Quarter Conference Call Details 2Health News:Common Medications May Harm Memory in Older People 2Health News:Common Medications May Harm Memory in Older People 3
...unctional microplate detection system, ,offers the...romising flexibility. ,The Ultra Evolution is Te...atform. New features are available as options whic...nt along with possible upgrade paths should your n...
...roplate based multi-detection reader which incorpo...uorescence Polarization , Fluorescence Intensity ...uminescence (flash and glow) , Absorbance ,It ...adioactive labeled applications:, , Ca2+ Measureme...
...e reader that offers four different measurement mo...e-resolved fluorescence, high-perfomance luminesce...ipped with injectors that deliver reagent at the p...ys can be performed easily and allowing the unit t...
ViewLux ultraHTS Microplate Imager
Medicine Products: